Loading…
← CockpitCompetitor Analysis › 600829.SS HPGC Renmintongtai Pharmaceutical Corporation Class AOpen in the cockpit ↗

HPGC Renmintongtai Pharmaceutical Corporation Class A600829.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 72
Mkt cap
$701M
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$32.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.2 pp
WACC 5.0%
Hurdle
-1 pp
Req g minus delivered
Close · CNYCN¥8.72
1D-10.0%
1W-12.4%
1M-2.4%
3M-18.9%
6M-6.1%
YTD-19.3%
1Y-10.2%
ATR %8.0%
52w lowhigh51.9% off high

What HPGC Renmintongtai Pharmaceutical does

Employees: 2,735

HPGC Renmintongtai Pharmaceutical at a glance

Size HPGC Renmintongtai Pharmaceutical (600829.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $701M, the 2897th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.72 on 18 Nov 2026.

Performance Over six months the shares fell 6.1%, against -15.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 4.3% over the last twelve months (peer median +3.5%); the operating margin is 2.5% (peer median 11.0%).

Valuation It trades at 0.6× enterprise value to sales against a peer median of 1.8× (3rd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.2 points above its cost of capital (5.0% WACC).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026600829.SS 95Peer median 86
Six months, rebased to 100: HPGC Renmintongtai Pharmaceutical against the median of its 20 peers (local-currency closes).

HPGC Renmintongtai Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥10.6BCN¥10.3BCN¥10.0BCN¥10.4BCN¥9.61B
Revenue growth—+3%-3%+8%—
Gross profitCN¥879MCN¥766MCN¥779MCN¥909MCN¥829M
EBITDAn/aCN¥286MCN¥363MCN¥474MCN¥450M
Net incomeCN¥159MCN¥134MCN¥213MCN¥292MCN¥264M
Free cash flowCN¥155MCN¥283MCN¥107MCN¥310MCN¥301M
Capital expenditureCN¥28.3MCN¥17.2MCN¥8.04MCN¥23.5MCN¥6.42M
Total debtCN¥1.91BCN¥2.10BCN¥2.33BCN¥2.33BCN¥2.23B

Quarterly statements and history in the cockpit →

HPGC Renmintongtai Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%-10%0%NVCT453449850009150570603998SGMT688799600351600530688566688658PHIL688488ANNX21863007056004792171600829.SS6-month return →1-month return →
Up and to the right = strong over both horizons. HPGC Renmintongtai Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%0×10×20×30×45344985000915688799600530688658688488SPARC2171600829.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HPGC Renmintongtai Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%49856039986003516005306885666884882186300705600829.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HPGC Renmintongtai Pharmaceutical is the large dot.

HPGC Renmintongtai Pharmaceutical competitors and peer comparison

How HPGC Renmintongtai Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HPGC Renmintongtai Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600829.SSPeer medianRank in peer set
1-month return-2.4%-7.0%8th highest of 21
6-month return-6.1%-15.3%9th highest of 21
Distance from 52-week high-51.9%-34.0%6th lowest of 21
Revenue growth (TTM)+4.3%+3.5%9th highest of 18
Operating margin2.5%11.0%5th lowest of 18
EV / Sales0.6×1.8×3rd cheapest of 18
Growth the price implies (Req g, 7 yrs)4.0%-2.0%4th most demanding of 10
Growth delivered (Del g)+5.3%+1.9%5th highest of 10
Hurdle (Req g minus delivered)-1.4 pp-5.4 pp4th most demanding of 10
ROIC minus cost of capital+0.2 pp+1.5 pp7th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%1.6×-8.3%-2.8%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a

Questions

Which companies are HPGC Renmintongtai Pharmaceutical's closest peers?
The cockpit's peer set: Nuvectis Pharma (NVCT), Mochida Pharmaceutical (4534.T), Earth (4985.T), Shandong Wit Dyne Health (000915.SZ), China Traditional Chinese Medicine (0570.HK), Hunan Fangsheng Pharmaceutical (603998.SS), Sagimet Biosciences (SGMT), Hunan Warrant Pharmaceutical (688799.SS).
Is HPGC Renmintongtai Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 0.6× against a peer median of 1.8×, 3rd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has HPGC Renmintongtai Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -6.1% against -15.3% for the median peer; over one year -10.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.